ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 081

Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

Simone Carbogno 1, Denise Pires Marafon 2, Giulia Marucci 2, Manuela Pardeo 2, Antonella Insalaco 2, Virginia Messia 2, Emanuela Sacco 2, Ferhat Demir 3, Betul Sozeri 3, Natasia Cekada 4, Marija Jelusic 4, Olga Vougiouka 5, Mikhail Kostik 6, Alenka Gagro 7, Christoph Kessel 8, Francesca Minoia 9, Fabrizio De Benedetti 2 and Claudia Bracaglia2, 1Pediatric Area, University of Milan, Milan, Italy, 2Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy, 3University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, 4Division of Paediatric Rheumatology and Immunology, University of Zagreb, Zagreb, Croatia, 5Second Department of Paediatrics, P. & A. Kyriakou Children’s Hospital, Athens, Greece, 6Saint-Petersburg State Pediatric Medical University, Saint-Petersburg, Russia, 7Children's Hospital Zagreb, Zagreb, Croatia, 8University Hospital Muenster, Muenster, Nordrhein-Westfalen, Germany, 9Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy

Meeting: 2020 Pediatric Rheumatology Symposium

Keywords: macrophage activation syndrome, risk, Systemic JIA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Title: Poster Session 2

Session Type: ACR Abstract Session

Session Time: 5:00PM-6:00PM

Background/Purpose: Macrophage Activation Syndrome (MAS) is a severe, life-threatening, complication of rheumatic diseases in childhood, particularly of systemic Juvenile Idiopathic Arthritis (sJIA), occurring in approximately 25% of the patients with sJIA. The mortality rate of MAS is still significantly high. A score that identify sJIA patients who are at high risk to develop MAS would be useful in clinical practice. There are no parameters available to identify from onset sJIA patients with high risk to develop MAS in their disease course.

Methods: We evaluated whether routine laboratory parameters at disease onset may predict the development of MAS in patients with active sJIA and we defined a risk score of MAS for sJIA patients using these parameters. Laboratory parameters of disease activity and severity (WBC, N, PLT, Hb, ferritin, AST, ALT, gGT, LDH, TGL, fibrinogen, D-dimer and CRP), were retrospectively evaluated in 85 sJIA patients referred to our Division of Rheumatology from 1998 to 2018 with at least one year of follow-up. Laboratory parameters were evaluated during active sJIA, without MAS, at time of hospitalization (T1) and immediately before treatment for sJIA was started (T2). Patients were divided in two groups: group 1 (sJIA patients without history of MAS), group 2 (sJIA patients with at least one MAS episode during disease course). To calculate a MAS risk score, laboratory parameters, collected at T2, with a statistically significant difference between the two groups of patients were selected.

Results: Thirty-two patients, that fulfilled the 2016 classification criteria for MAS [1] at time of sampling, were excluded from the analysis. Therefore, we analysed laboratory parameters of 53 patients with sJIA, 33 of whom without history of MAS (group 1) and 20 who developed at least one episode of MAS during disease course (group 2). Levels of ferritin, AST, LDH, gGT and TGL, collected at T2, were statistically significant higher in patients with a history of MAS compared to those without a history of MAS. For each of these parameters an arbitrary cut-off was defined. In order to define the final score an arbitrary rate was attributed to each parameter (Table1). Sensitivity (Se), specificity (Sp), positive predictive value (PPV) and negative predictive value (NPV) were calculated to define the best scoring system. The scoring system with the best sensitivity was chosen (Table 2). A MAS risk score >3 identified 19 out of 20 sJIA patients with a history of MAS and 5 out of 33 sJIA patients without history of MAS. 

In order to validate the MAS risk score on a different population, we applied the score on 47 patients from other paediatric Rheumatologic centres, 29 without history of MAS and 18 with at least one episode of MAS. Sensitivity and specificity of the score are reported in table 3.

Conclusion: In conclusion we developed a MAS risk score based on routine laboratory parameters, available worldwide, that can help clinicians to identify these patients early in the disease course. The initial validation analysis is promising but to validate the score a larger population is needed.

Reference

  1. Ravelli A et al. Ann Rheum Dis. 2016 Mar;75(3):481-9.

Table 1. Laboratory parameters and cut_off used to create the MAS risk score in sJIA patients.

Table 2. Sensitivity and Specificity of the best Risk core

Table 3. Sensitivity and Specificity of the MAS risk score in the validation cohort.


Disclosure: S. Carbogno, None; D. Pires Marafon, None; G. Marucci, None; M. Pardeo, None; A. Insalaco, None; V. Messia, None; E. Sacco, None; F. Demir, None; B. Sozeri, None; N. Cekada, None; M. Jelusic, None; O. Vougiouka, None; M. Kostik, None; A. Gagro, None; C. Kessel, None; F. Minoia, None; F. De Benedetti, Novartis, 1, 2, Novimmune, 1, Sobi, 1, 2, Roche, 1, 2, Pfizer, 1, Sanofi, 1, AbbVie, 1, Novimmune/Sobi, 1; C. Bracaglia, None.

To cite this abstract in AMA style:

Carbogno S, Pires Marafon D, Marucci G, Pardeo M, Insalaco A, Messia V, Sacco E, Demir F, Sozeri B, Cekada N, Jelusic M, Vougiouka O, Kostik M, Gagro A, Kessel C, Minoia F, De Benedetti F, Bracaglia C. Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 4). https://acrabstracts.org/abstract/risk-score-of-macrophage-activation-syndrome-in-patients-with-systemic-juvenile-idiopathic-arthritis-3/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2020 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-score-of-macrophage-activation-syndrome-in-patients-with-systemic-juvenile-idiopathic-arthritis-3/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology